[Hydroxyethyl starch-induced transient renal failure in preexisting glomerular damage].
Hemorheological therapy through hemodilution has been gaining importance for several years and been applied to an ever increasing degree in stationary as well as in ambulant treatment. While renal insufficiency without previously established nephropathy is known to be a side effect of dextrans, cases of HES-induced nephropathy have so far not been reported. Two cases are presented in which in the course of stationary hemodilution therapy with HES an acute deterioration of an already exiting nephropathy was noted. Possible pathophysiological causes for such a deterioration are most likely to be found in an increased permeability of the glomerular basal lamina. Hydroxyethyl starch molecules are filtered above the physiological renal threshold which increases the viscosity of the primary urine. This can be counteracted by increasing diuresis. This conclusion can be drawn from our own observations which proved that renal insufficiency can be avoided through sufficient fluid intake (approx. 3 liters/day). In patients with creatinine values above 1.5/dl and arterial hypertension the indication for hemodilution therapy must be analysed carefully. If hemodilution therapy proves to be necessary, sufficient fluid intake must be guaranteed. Retention parameters must be controlled every other day in the course of the therapy. As an alternative, the administration of gelatin preparations should be considered as it does not cause cumulation.
Waldhausen
P
P
Abteilung für Klinische Hämostaseologie und Transfusionsmedizin, Universitätskliniken des Saarlandes, Homburg/Saar, BRD.
Kiesewetter
H
H
Leipnitz
G
G
Scielny
J
J
Jung
F
F
Bambauer
R
R
von Blohn
G
G
D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced*; D000368:Aged; D002544:Cerebral Infarction / Q000097:blood / Q000628:therapy; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications; D003925:Diabetic Angiopathies / Q000097:blood / Q000628:therapy*; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications*; D003930:Diabetic Retinopathy / Q000097:blood / Q000628:therapy*; D005260:Female; D006438:Hemodilution / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000009:adverse effects*; D012307:Risk Factors; D014508:Urea / Q000097:blood
D006895:Hydroxyethyl Starch Derivatives; D014508:Urea
Durch Hydroxyäthylstärke induzierte passagere Niereninsuffizienz bei vorbestehender glomerulärer Schädigung.